Nearly 120 million adults in the United States have hypertension, and just 1 in 4 of them have it under control. Treatments remain limited outside of lifestyle changes and hypertensive medications that are not always effective.  

Michael Minogue spent nearly two decades as the chairman, president and CEO of Abiomed, and now he is running to be the next governor of Massachusetts. 

New research suggests there may be a cardiovascular benefit to considering dual antiplatelet therapy for valve-in-valve TAVR patients.

Using an Impella heart pump during high-risk PCI was linked to a reduced short-term mortality rate and an acceptable safety profile.

Are too many low-risk patients with severe AS undergoing TAVR instead of SAVR? According to one group of clinicians, "a significant public health concern may be looming."

More and more TAVR patients are going to require SAVR later in life. A research team out of Cleveland Clinic hoped to learn more about how this one-two combination may impact long-term outcomes.

The next-generation Watchman device is designed to better seal off complex LAA anatomy in a variety of LAA shapes and sizes.

"The key question isn't just whether a device works, but whether it makes procedures more efficient and provides physicians with a more predictable tool for treating patients with complex arterial disease," explained co-principal investigator Venita Chandra, MD, clinical professor of surgery at Stanford Health Care.